Search Result

Results for "

PRMT5 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Bcl-2 Family (1) BCL6 (1) CDK (1) EGFR (1) Fluorescent Dye (1) HDAC (1) Histone Methyltransferase (79) MDM-2/p53 (1) Parasite (2) Phosphodiesterase (PDE) (2) Potassium Channel (1) PROTACs (2) SARS-CoV (1) WDR5 (1)
By Research Areas:	Cancer (80) Infection (3) Inflammation/Immunology (3) Metabolic Disease (1)
Oligonucleotides:	Aptamers (1)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Q36691

PRMT5-IN-30	Histone Methyltransferase	Cancer
PRMT5-IN-30 (compound 17) is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 0.33 μM and a K_d of 0.987 μM. PRMT5-IN-30 exhibits a broad selectivity against a panel of other methyltransferases. PRMT5-IN-30 inhibits PRMT5 mediated SmD3 methylation .

HY-153390

AMG-193	Histone Methyltransferase	Cancer
AMG 193 is an orally active MTA-cooperative *PRMT5* inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting *PRMT5* (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-148674

PRMT5-IN-25	Histone Methyltransferase	Cancer
PRMT5-IN-25 (compound 503) is a potent *PRMT5* inhibitor with an K_i value of 0.06 nM. PRMT5-IN-25 shows antiproliferative .

HY-144189

PRMT5-IN-18	Histone Methyltransferase	Cancer
PRMT5-IN-18 (Compound 002) is a potent *PRMT5* inhibitor that can be used for the research of a disease mediated by PRMT5， such as cancer .

HY-160029

PRMT5-IN-32	Histone Methyltransferase	Cancer
PRMT5-IN-32 is an inhibitor of *PRMT5. PRMT5-IN-32 inhibits* HCT116 cell proliferation with an IC ₅₀ of 0.13 μM .

HY-144188

PRMT5-IN-17	Histone Methyltransferase	Cancer
PRMT5-IN-17 (Compound 6) is a *PRMT5* inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

HY-144187

PRMT5-IN-16	Histone Methyltransferase	Cancer
PRMT5-IN-16 (Compound 20) is a *PRMT5* inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

HY-168263

PRMT5-IN-45	Histone Methyltransferase Apoptosis	Cancer
PRMT5-IN-45 (compound 36) is a potent and selective *PRMT5* inhibitor with an IC₅₀ of 3 nM. PRMT5-IN-45 potently reduces the level of symmetric dimethylarginines (sDMA) and inhibits the proliferation of MOLM-13 cell lines by inducing apoptosis and cell cycle arrest .

HY-163592

PRMT5-IN-43	Histone Methyltransferase	Cancer
PRMT5-IN-43 (compound 4A) is a *PRMT5* inhibitor. PRMT5-IN-43 can be used in cancer research .

HY-163593

PRMT5-IN-44	Histone Methyltransferase	Cancer
PRMT5-IN-44 (compound 12) is a *PRMT5* inhibitor. PRMT5-IN-44 can be used in cancer research .

HY-163587

PRMT5-IN-39-d3	Histone Methyltransferase	Cancer
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-163591

PRMT5-IN-36-d3	Histone Methyltransferase	Cancer
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research .

HY-168842

PRMT5-IN-47	Histone Methyltransferase	Cancer
PRMT5-IN-47 (compound 20) is a potent, selectively and orally active, MTA cooperative *PRMT5* inhibitor with an IC₅₀ value of 15 nM. PRMT5-IN-47 shows antiproliferative activity. PRMT5-IN-47 shows anticancer activity .

HY-142211

PRMT5-IN-15	Histone Methyltransferase	Cancer
PRMT5-IN-15 is a *PRMT5* inhibitor with an IC₅₀ value of 0.84 nM.

HY-163589

PRMT5-IN-40	Histone Methyltransferase	Others
PRMT5-IN-40 (compound 104) is a potent inhibitor of *PRMT5* .

HY-163590

PRMT5-IN-41	Histone Methyltransferase Potassium Channel	Cancer
PRMT5-IN-41 (compound 130) is a potent and orally active *PRMT5* inhibitor. PRMT5-IN-41 inhibits hERG ion channel with IC₅₀ value of 1.36 µM .

HY-162230

PRMT5-IN-33	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-33 (compound A8) is a selective, SAM-competitve *PRMT5* inhibitors with IC₅₀ of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity .

HY-153422

PRMT5-IN-29	Histone Methyltransferase	Cancer
PRMT5-IN-29 is a potent and orally active *PRMT5* Inhibitor with an IC₅₀ of 1.5 μΜ. PRMT5-IN-29 has the potential for advanced cancers research .

HY-134883

PRMT5-IN-4	Histone Methyltransferase	Others
PRMT5-IN-4 (compound AAA-1) is a *PRMT5* inhibitor .

HY-141875

PRMT5-IN-13	Histone Methyltransferase	Cancer
PRMT5-IN-13 is a selective inhibitor of protein arginine methyltransferase 5 (prmt5).

HY-169708

PRMT5-IN-49	Histone Methyltransferase	Cancer
PRMT5-IN-49 (Compound 4b16) is an inhibitor of *PRMT5* .

HY-150081

PRMT5-IN-21	Histone Methyltransferase	Cancer
PRMT5-IN-21 (compound 1) is a potent cyclonucleoside *PRMT5* inhibitor .

HY-155050

PRMT5-IN-31	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-31 (Compound 3m) is a selective *PRMT5* inhibitor (IC₅₀: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T_1/2: 132.4 min) .

HY-153057

PRMT5-IN-46	Histone Methyltransferase	Metabolic Disease Cancer
PRMT5-IN-46 (compound 278) inhibits *PRMT5* with IC₅₀ of 1-10 μM. *PRMT5* is a methyltransferase which is associated with specific genetic alterations. PRMT5-IN-46 can be used for research of proliferative diseases, metabolic disorders, and blood diseases .

HY-160865

PRMT5-IN-35	Histone Methyltransferase	Cancer
PRMT5-IN-35 (Compound 87) is a potent, selective and orally active *PRMT5* inhibitor with an IC₅₀ value of 1 nM . PRMT5-IN-35 can be used in cancer research .

HY-156680

TNG-462	Histone Methyltransferase	Cancer
TNG-462 is an orally active and selective *PRMT5* inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers .

HY-132937

PRMT5-IN-9	Histone Methyltransferase	Cancer
PRMT5-IN-9 is a novel PRMT5 inhibitor for researching cancer, with an IC₅₀ of 0.01 μM.

HY-158143

PRMT5-IN-34	Histone Methyltransferase	Cancer
PRMT5-IN-34 (Compound C) is an inhibitor of MTA-cooperative Protein arginine methyltransferase 5 (PRMT5/MAT) .

HY-163585

PRMT5-IN-36	Histone Methyltransferase	Cancer
PRMT5-IN-36 (compound 4) is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-111213

PRMT5-IN-20	Histone Methyltransferase	Cancer
PRMT5-IN-20 is a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with anti-tumor activity .

HY-163588

PRMT5-IN-39	Histone Methyltransferase	Cancer
PRMT5-IN-39 (compound 107) is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-163586

PRMT5-IN-37	Histone Methyltransferase	Cancer
PRMT5-IN-37 (compound 29) is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-170603

PRMT5-targeted fluorescent ligand-1	Fluorescent Dye Histone Methyltransferase Apoptosis	Cancer
PRMT5-targeted fluorescent ligand-1 (Compound 7) is a *PRMT5*-targeted fluorescent ligand, that inhibits *PRMT5* with an IC₅₀ of 29.39 nM. PRMT5-targeted fluorescent ligand-1 exhibits cell imaging activity, that exhibits good fluorescence signal in MCF-7 with an IC₅₀ of 29 nM. PRMT5-targeted fluorescent ligand-1 induces apoptosis. PRMT5-targeted fluorescent ligand-1 exhibits a maximal excitation wavelength of 438 nm and a maximal emission wavelength of 550 nm .

HY-149005

PRMT5-IN-19	Histone Methyltransferase	Cancer
PRMT5-IN-19 (Compound 41) is an selective orally active non-nucleoside *PRMT5* inhibitor with IC₅₀ values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). PRMT5-IN-19 can occupy the SAM-binding pocket in PRMT5 and block methyltransferase activity, which displays good selectivity over other PRMTs and PKMTs. PRMT5-IN-19 inhibits cell proliferation by inducing cell apoptosis, and can be used for cancer-related research .

HY-139611

Navlimetostat 3 Publications Verification MRTX-1719	Histone Methyltransferase	Cancer
Navlimetostat is a potent, orally active, selective *PRMT5•MTA* complex inhibitor, with IC₅₀ of 3.6 and 20.5 nM for *PRMT5•MTA* and *PRMT5. Navlimetostat binds to the PRMT5•MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-132309

BRD0639 1 Publications Verification	Histone Methyltransferase	Cancer
BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities .

HY-163799

PRMT5-MTA-IN-1	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase *PRMT5-MTA. PRMT5-MTA-IN-1 inhibits* the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC₅₀ of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-141876

PRMT5-IN-14	Histone Methyltransferase	Cancer
PRMT5-IN-14 is a *PRMT5* inhibitor to research cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

HY-126256

PRMT5-IN-1	Histone Methyltransferase	Cancer
PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-P3822

PRMT5-IN-23	Histone Methyltransferase	Cancer
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. *PRMT5* is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

HY-126256A

PRMT5-IN-1 hydrochloride	Histone Methyltransferase	Cancer
PRMT5 IN-1 hydrochloride (compound 9), a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 hydrochloride can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-170792

PRMT5-IN-48	Histone Methyltransferase	Cancer
PRMT5-IN-48 (compound D3) is an orally effective *PRMT5* inhibitor (IC₅₀=20.7 nM) with anticancer activity. PRMT5-IN-48 can inhibit the growth of various cancer cells, induce apoptosis (apoptosis), and arrest the cell cycle at the G0/G1 phase. PRMT5-IN-48 can be used for non-Hodgkin lymphoma (NHL) research .

HY-151576

PRMT5:MEP50 PPI	Histone Methyltransferase	Cancer
PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells .

HY-162989

PRMT5-MTA-IN-2	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-2 (compund 1) is a MTA co-inhibitor of *PRMT5* with IC₅₀ less than 1.5 nM .

HY-163434

PRMT5/EGFR-IN-1	EGFR Histone Methyltransferase	Cancer
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual *PRMT5/EGFR* inhibitor, with IC₅₀s of 15.47 and 19.31 μM, respectively. PRMT5/EGFR-IN-1 exhibits antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines. PRMT5/EGFR-IN-1 has favorable in vivo PK and PD properties. PRMT5/EGFR-IN-1 can significantly inhibit the growth of MCF7 orthotopic xenograft tumors .

HY-112165

PRMT5-IN-2	Histone Methyltransferase	Cancer
PRMT5-IN-2 is a rotein arginine methyltransferase 5 (PRMT5) inhibitor extracted from patent WO2018130840A1, compound 3 .

HY-139611C

Navlimetostat hydrochloride 3 Publications Verification MRTX-1719 hydrochloride	Histone Methyltransferase	Cancer
Navlimetostat hydrochloride is a potent first-in-class selective inhibitor of the *PRMT5/MTA* complex, with an IC₅₀ of less than 10 nM in PRMT5/MTA MTAP ^DEL SDMA cells .

HY-131493

PF-06939999 PRMT5-IN-3	Histone Methyltransferase	Cancer
PF-06939999 (PRMT5-IN-3) is a *PRMT5* inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents.

HY-107777

LLY-283 3 Publications Verification	Histone Methyltransferase	Cancer
LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC₅₀ of 22 nM and a K_d of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.

HY-124131

DS-437 1 Publications Verification	Histone Methyltransferase	Inflammation/Immunology Cancer
DS-437 is a dual *PRMT5/7* inhibitor (IC₅₀s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC₅₀s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3 .

Cat. No.	Product Name	Target	Research Area

HY-P3822

PRMT5-IN-23	Histone Methyltransferase	Cancer
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. *PRMT5* is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

Cat. No.	Product Name	Chemical Structure

HY-163587

PRMT5-IN-39-d3
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-163591

PRMT5-IN-36-d3
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research .

Cat. No.	Product Name		Classification

HY-147081

AS 1411 AGRO-100		Aptamers
AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: